Advertisement

IGFBP-3 interacts with NONO and SFPQ in PARP-dependent DNA damage repair in triple-negative breast cancer

  • Hasanthi C. de Silva
  • Mike Z. Lin
  • Leo Phillips
  • Janet L. Martin
  • Robert C. BaxterEmail author
Original Article
  • 65 Downloads

Abstract

Women with triple-negative breast cancer (TNBC) are generally treated by chemotherapy but their responsiveness may be blunted by DNA double-strand break (DSB) repair. We previously reported that IGFBP-3 forms nuclear complexes with EGFR and DNA-dependent protein kinase (DNA-PKcs) to modulate DSB repair by non-homologous end-joining (NHEJ) in TNBC cells. To discover IGFBP-3 binding partners involved in chemoresistance through stimulation of DSB repair, we analyzed the IGFBP-3 interactome by LC–MS/MS and confirmed interactions by coimmunoprecipitation and proximity ligation assay. Functional effects were demonstrated by DNA end-joining in vitro and measurement of γH2AX foci. In response to 20 µM etoposide, the DNA/RNA-binding protein, non-POU domain-containing octamer-binding protein (NONO) and its dimerization partner splicing factor, proline/glutamine-rich (SFPQ) formed complexes with IGFBP-3, demonstrated in basal-like TNBC cell lines HCC1806 and MDA-MB-468. NONO binding to IGFBP-3 was also shown in a cell-free biochemical assay. IGFBP-3 complexes with NONO and SFPQ were blocked by inhibiting EGFR with gefitinib or DNA-PKcs with NU7026, and by the PARP inhibitors veliparib and olaparib, which also reduced DNA end-joining activity and delayed the resolution of the γH2AX signal (i.e. inhibited DNA DSB repair). Downregulation of the long noncoding RNA in NHEJ pathway 1 (LINP1) by siRNA also blocked IGFBP-3 interaction with NONO–SFPQ. These findings suggest a PARP-dependent role for NONO and SFPQ in IGFBP-3-dependent DSB repair and the involvement of LINP1 in the complex formation. We propose that targeting of the DNA repair function of IGFBP-3 may enhance chemosensitivity in basal-like TNBC, thus improving patient outcomes.

Keywords

IGF binding protein TNBC P54NRB PSF lncRNA PARP inhibitors 

Notes

Acknowledgements

This work was supported by Grants DP140100137 from the Australian Research Council and IN-17-040 from the National Breast Cancer Foundation, Australia, to RCB.

Author contributions

The study was designed by RCB. Data were collected and analysed by HCdS, MZL, LP, JLM and RCB. The manuscript was drafted by RCB. All authors revised the article critically for intellectual content and gave their approval of this version to be published.

Compliance with ethical standards

Conflict of interest

All authors declare that they have no competing interests.

Supplementary material

18_2019_3033_MOESM1_ESM.pdf (42 kb)
Supplementary material 1 (PDF 41 kb)
18_2019_3033_MOESM2_ESM.pdf (52 kb)
Supplementary material 2 (PDF 51 kb)
18_2019_3033_MOESM3_ESM.pdf (471 kb)
Supplementary material 3 (PDF 470 kb)
18_2019_3033_MOESM4_ESM.pdf (414 kb)
Supplementary material 4 (PDF 413 kb)

References

  1. 1.
    Khanna A (2015) DNA damage in cancer therapeutics: a boon or a curse? Cancer Res 75:2133–2138CrossRefGoogle Scholar
  2. 2.
    Rulten SL, Grundy GJ (2017) Non-homologous end joining: common interaction sites and exchange of multiple factors in the DNA repair process. BioEssays 39:1600209CrossRefGoogle Scholar
  3. 3.
    Denkert C, Liedtke C, Tutt A, von Minckwitz G (2017) Molecular alterations in triple-negative breast cancer—the road to new treatment strategies. Lancet 389:2430–2442CrossRefGoogle Scholar
  4. 4.
    Abbotts R, Wilson DM 3rd (2017) Coordination of DNA single strand break repair. Free Radic Biol Med 107:228–244CrossRefGoogle Scholar
  5. 5.
    Beck C, Robert I, Reina-San-Martin B, Schreiber V, Dantzer F (2014) Poly(ADP-ribose) polymerases in double-strand break repair: focus on PARP1, PARP2 and PARP3. Exp Cell Res 329:18–25CrossRefGoogle Scholar
  6. 6.
    Dittmann K, Mayer C, Fehrenbacher B, Schaller M, Raju U, Milas L, Chen DJ, Kehlbach R, Rodemann HP (2005) Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J Biol Chem 280:31182–31189CrossRefGoogle Scholar
  7. 7.
    Nowsheen S, Bonner JA, Yang ES (2011) The poly(ADP-Ribose) polymerase inhibitor ABT-888 reduces radiation-induced nuclear EGFR and augments head and neck tumor response to radiotherapy. Radiother Oncol 99:331–338CrossRefGoogle Scholar
  8. 8.
    Krietsch J, Caron MC, Gagne JP, Ethier C, Vignard J, Vincent M, Rouleau M, Hendzel MJ, Poirier GG, Masson JY (2012) PARP activation regulates the RNA-binding protein NONO in the DNA damage response to DNA double-strand breaks. Nucl Acids Res 40:10287–10301CrossRefGoogle Scholar
  9. 9.
    Jaafar L, Li Z, Li S, Dynan WS (2017) SFPQ*NONO and XLF function separately and together to promote DNA double-strand break repair via canonical nonhomologous end joining. Nucl Acids Res 45:1848–1859CrossRefGoogle Scholar
  10. 10.
    Lin MZ, Marzec KA, Martin JL, Baxter RC (2014) The role of insulin-like growth factor binding protein-3 in the breast cancer cell response to DNA-damaging agents. Oncogene 33:85–96CrossRefGoogle Scholar
  11. 11.
    Baxter RC (2014) IGF binding proteins in cancer: mechanistic and clinical insights. Nat Rev Cancer 14:329–341CrossRefGoogle Scholar
  12. 12.
    Martin JL, de Silva HC, Lin MZ, Scott CD, Baxter RC (2014) Inhibition of insulin-like growth factor-binding protein-3 signaling through sphingosine kinase-1 sensitizes triple-negative breast cancer cells to EGF receptor blockade. Mol Cancer Therap 13:316–328CrossRefGoogle Scholar
  13. 13.
    Hunt NJ, Phillips L, Waters KA, Machaalani R (2016) Proteomic MALDI-TOF/TOF-IMS examination of peptide expression in the formalin fixed brainstem and changes in sudden infant death syndrome infants. J Proteom 138:48–60CrossRefGoogle Scholar
  14. 14.
    Andrin C, Hendzel MJ (2004) F-actin-dependent insolubility of chromatin-modifying components. J Biol Chem 279:25017–25023CrossRefGoogle Scholar
  15. 15.
    Andrin C, McDonald D, Attwood KM, Rodrigue A, Ghosh S, Mirzayans R, Masson JY, Dellaire G, Hendzel MJ (2012) A requirement for polymerized actin in DNA double-strand break repair. Nucleus 3:384–395CrossRefGoogle Scholar
  16. 16.
    Hollick JJ, Golding BT, Hardcastle IR, Martin N, Richardson C, Rigoreau LJ, Smith GC, Griffin RJ (2003) 2,6-disubstituted pyran-4-one and thiopyran-4-one inhibitors of DNA-dependent protein kinase (DNA-PK). Bioorg Med Chem Lett 13:3083–3086CrossRefGoogle Scholar
  17. 17.
    Scully R, Xie A (2013) Double strand break repair functions of histone H2AX. Mutat Res 750:5–14CrossRefGoogle Scholar
  18. 18.
    Bond CS, Fox AH (2009) Paraspeckles: nuclear bodies built on long noncoding RNA. J Cell Biol 186:637–644CrossRefGoogle Scholar
  19. 19.
    Dianatpour A, Ghafouri-Fard S (2017) The role of long non coding RNAs in the repair of DNA double strand breaks. Int J Mol Cell Med 6:1–12Google Scholar
  20. 20.
    Wu Z, Wang Y (2017) Studies of lncRNAs in DNA double strand break repair: what is new? Oncotarget 8:102690–102704Google Scholar
  21. 21.
    Zhang Y, He Q, Hu Z, Feng Y, Fan L, Tang Z, Yuan J, Shan W, Li C, Hu X et al (2016) Long noncoding RNA LINP1 regulates repair of DNA double-strand breaks in triple-negative breast cancer. Nat Struct Mol Biol 23:522–530CrossRefGoogle Scholar
  22. 22.
    Desai A, Yan Y, Gerson SL (2018) Advances in therapeutic targeting of the DNA damage response in cancer. DNA Repair (Amst) 66–67:24–29CrossRefGoogle Scholar
  23. 23.
    Pannunzio NR, Watanabe G, Lieber MR (2018) Nonhomologous DNA end joining for repair of DNA double-strand breaks. J Biol Chem 293:10512–10523CrossRefGoogle Scholar
  24. 24.
    Kakarougkas A, Jeggo PA (2014) DNA DSB repair pathway choice: an orchestrated handover mechanism. Br J Radiol 87:20130685CrossRefGoogle Scholar
  25. 25.
    Montecucco A, Zanetta F, Biamonti G (2015) Molecular mechanisms of etoposide. Excli J 14:95–108Google Scholar
  26. 26.
    Udayakumar D, Dynan WS (2015) Characterization of DNA binding and pairing activities associated with the native SFPQ. NONO DNA repair protein complex. Biochem Biophys Res Commun 463:473–478CrossRefGoogle Scholar
  27. 27.
    Knott GJ, Bond CS, Fox AH (2016) The DBHS proteins SFPQ, NONO and PSPC1: a multipurpose molecular scaffold. Nucl Acids Res 44:3989–4004CrossRefGoogle Scholar
  28. 28.
    Ren S, She M, Li M, Zhou Q, Liu R, Lu H, Yang C, Xiong D (2014) The RNA/DNA-binding protein PSF relocates to cell membrane and contributes cells’ sensitivity to antitumor drug, doxorubicin. Cytometr A 85:231–241CrossRefGoogle Scholar
  29. 29.
    Liang Y, Li Y, Song X, Zhang N, Sang Y, Zhang H, Liu Y, Chen B, Zhao W, Wang L et al (2018) Long noncoding RNA LINP1 acts as an oncogene and promotes chemoresistance in breast cancer. Cancer Biol Ther 19:120–131CrossRefGoogle Scholar
  30. 30.
    Wang X, Liu H, Shi L, Yu X, Gu Y, Sun X (2018) LINP1 facilitates DNA damage repair through non-homologous end joining (NHEJ) pathway and subsequently decreases the sensitivity of cervical cancer cells to ionizing radiation. Cell Cycle 17:439–447CrossRefGoogle Scholar
  31. 31.
    Rodemann HP, Dittmann K, Toulany M (2007) Radiation-induced EGFR-signaling and control of DNA-damage repair. Int J Radiat Biol 83:781–791CrossRefGoogle Scholar
  32. 32.
    Morchikh M, Cribier A, Raffel R, Amraoui S, Cau J, Severac D, Dubois E, Schwartz O, Bennasser Y, Benkirane M (2017) HEXIM1 and NEAT1 long non-coding RNA form a multi-subunit complex that regulates DNA-mediated innate immune response. Mol Cell 67:387–399CrossRefGoogle Scholar
  33. 33.
    Ji Q, Zhang L, Liu X, Zhou L, Wang W, Han Z, Sui H, Tang Y, Wang Y, Liu N et al (2014) Long non-coding RNA MALAT1 promotes tumour growth and metastasis in colorectal cancer through binding to SFPQ and releasing oncogene PTBP2 from SFPQ/PTBP2 complex. Br J Cancer 111:736–748CrossRefGoogle Scholar
  34. 34.
    Yang P, Chen T, Xu Z, Zhu H, Wang J, He Z (2016) Long noncoding RNA GAPLINC promotes invasion in colorectal cancer by targeting SNAI2 through binding with PSF and NONO. Oncotarget 7:42183–42194Google Scholar
  35. 35.
    Firth SM, Baxter RC (2002) Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 23:824–854CrossRefGoogle Scholar
  36. 36.
    Lee KW, Cohen P (2002) Nuclear effects: unexpected intracellular actions of insulin-like growth factor binding protein-3. J Endocrinol 175:33–40CrossRefGoogle Scholar
  37. 37.
    Ingermann AR, Yang YF, Han J, Mikami A, Garza AE, Mohanraj L, Fan L, Idowu M, Ware JL, Kim HS et al (2010) Identification of a novel cell death receptor mediating IGFBP-3-induced anti-tumor effects in breast and prostate cancer. J Biol Chem 285:30233–30246CrossRefGoogle Scholar
  38. 38.
    Agostini-Dreyer A, Jetzt AE, Stires H, Cohick WS (2015) Endogenous IGFBP-3 mediates intrinsic apoptosis through modulation of Nur77 phosphorylation and nuclear export. Endocrinology 156:4141–4151CrossRefGoogle Scholar
  39. 39.
    Hollowood AD, Lai T, Perks CM, Newcomb PV, Alderson D, Holly JM (2000) IGFBP-3 prolongs the p53 response and enhances apoptosis following UV irradiation. Int J Cancer 88:336–341CrossRefGoogle Scholar
  40. 40.
    Grkovic S, O’Reilly VC, Han S, Hong M, Baxter RC, Firth SM (2013) IGFBP-3 binds GRP78, stimulates autophagy and promotes the survival of breast cancer cells exposed to adverse microenvironments. Oncogene 32:2412–2420CrossRefGoogle Scholar
  41. 41.
    Granata R, Trovato L, Garbarino G, Taliano M, Ponti R, Sala G, Ghidoni R, Ghigo E (2004) Dual effects of IGFBP-3 on endothelial cell apoptosis and survival: involvement of the sphingolipid signaling pathways. FASEB J 18:1456–1458CrossRefGoogle Scholar
  42. 42.
    Burrows C, Holly JM, Laurence NJ, Vernon EG, Carter JV, Clark MA, McIntosh J, McCaig C, Winters ZE, Perks CM (2006) Insulin-like growth factor binding protein 3 has opposing actions on malignant and nonmalignant breast epithelial cells that are each reversible and dependent upon cholesterol-stabilized integrin receptor complexes. Endocrinology 147:3484–3500CrossRefGoogle Scholar
  43. 43.
    Baxter RC (2015) Nuclear actions of insulin-like growth factor binding protein-3. Gene 569:7–13CrossRefGoogle Scholar
  44. 44.
    Mathur M, Tucker PW, Samuels HH (2001) PSF is a novel corepressor that mediates its effect through Sin3A and the DNA binding domain of nuclear hormone receptors. Mol Cell Biol 21:2298–2311CrossRefGoogle Scholar
  45. 45.
    Liu B, Lee HY, Weinzimer SA, Powell DR, Clifford JL, Kurie JM, Cohen P (2000) Direct functional interactions between insulin-like growth factor-binding protein-3 and retinoid X receptor-alpha regulate transcriptional signaling and apoptosis. J Biol Chem 275:33607–33613CrossRefGoogle Scholar
  46. 46.
    Sonnenblick A, de Azambuja E, Azim HA Jr, Piccart M (2015) An update on PARP inhibitors–moving to the adjuvant setting. Nat Rev Clin Oncol 12:27–41CrossRefGoogle Scholar
  47. 47.
    Sallmyr A, Tomkinson AE (2018) Repair of DNA double-strand breaks by mammalian alternative end-joining pathways. J Biol Chem 293:10536–10546CrossRefGoogle Scholar
  48. 48.
    Ruscetti T, Lehnert BE, Halbrook J, Le Trong H, Hoekstra MF, Chen DJ, Peterson SR (1998) Stimulation of the DNA-dependent protein kinase by poly(ADP-ribose) polymerase. J Biol Chem 273:14461–14467CrossRefGoogle Scholar
  49. 49.
    Schedlich LJ, Nilsen T, John AP, Jans DA, Baxter RC (2003) Phosphorylation of insulin-like growth factor binding protein-3 by deoxyribonucleic acid-dependent protein kinase reduces ligand binding and enhances nuclear accumulation. Endocrinology 144:1984–1993CrossRefGoogle Scholar
  50. 50.
    Zhang Q, Steinle JJ (2013) DNA-PK phosphorylation of IGFBP-3 is required to prevent apoptosis in retinal endothelial cells cultured in high glucose. Invest Ophthalmol Vis Sci 54:3052–3057CrossRefGoogle Scholar
  51. 51.
    Nowsheen S, Cooper T, Stanley JA, Yang ES (2012) Synthetic lethal interactions between EGFR and PARP inhibition in human triple negative breast cancer cells. PLoS One 7:e46614CrossRefGoogle Scholar
  52. 52.
    Ying S, Chen Z, Medhurst AL, Neal JA, Bao Z, Mortusewicz O, McGouran J, Song X, Shen H, Hamdy FC et al (2016) DNA-PKcs and PARP1 bind to unresected stalled DNA replication forks where they recruit XRCC1 to mediate repair. Cancer Res 76:1078–1088CrossRefGoogle Scholar
  53. 53.
    Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple-negative breast cancer. N Engl J Med 363:1938–1948CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Kolling Institute, Royal North Shore HospitalThe University of SydneySt. LeonardsAustralia
  2. 2.Orange Family Medical CentreOrangeAustralia

Personalised recommendations